A Study of Galunisertib on the Immune System in Participants With Cancer
The main purpose of this study is to learn more about how the study drug called galunisertib affects the immune system in participants with cancer. The study treatment is expected to last about six months for each participant, not including screening or follow-up.
Neoplasm
DRUG: Galunisertib
Change from Baseline in Immune Cell Subsets, Baseline up to Cycle 6 (Cycle = 28 Days)|Change from Baseline in Serum Cytokines, Baseline up to Cycle 6 (Cycle = 28 Days)|Change from Baseline in Humoral Immunity, Baseline up to Cycle 6 (Cycle = 28 Days)
Pharmacokinetics: Area Under the Concentration Time Curve of Galunisertib, Cycles 1 and 2: Predose on Day 1, Day 14 and Day 15
The main purpose of this study is to learn more about how the study drug called galunisertib affects the immune system in participants with cancer. The study treatment is expected to last about six months for each participant, not including screening or follow-up.